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Thrombotytir therapy has ixeo documented to reduce 
acute mvwardial infarct sire. The weviauslv established 
relation .between initial ST em& &v&n and final 
electmwdicgraphic (ECG) myorsrdial infarct size in pa 
tttnts without coronary reperfusion might thrretorr he 
altered by thrombolytic therapy. The effect of intravenw 
streptokibasc on this r&lion’& tkerefare studied in 73 
patients with inltinl acute myoeardial infaretian who had 
pnrtifipated in the Second fnlernatiomd Study ot Infarct 
Survival WS-2). Patients who received streptokinaw were 
considered 11s one croup and ralienl9 wha did not receive 
sireptokinsso as B &&I group. Final myocardial infarct 
size, rbick WE Lstimated from the QRS score, was pre- 
dirted fmm the admtssion standard KG by previo&ly 
developed fcwmtdns based on ST wgmont elevation. 
from prfdkkd to final mycxdk3l Infarct dze (I1Rz 0 
21.9% verws 16.2%; p < 0.0002~. This- WI ..,md 
for both aotertor (mfdtan 23.7% ver806 19.5%; p < z 03) 
and inferior (m&an 21.9% “erws 12.0%: p = 0.W 
tntsrct lotions. Multiple rt@&a an@& ad.iuntb% for 
differeMer in predii infarct adze amSmted UK slmdll. 
czm~e ofstrept&ppe 00 the dtEerence in Marct skip = 
o.t!w Bwed on the wintdttty cd the percent ctwlg3 fmm 
oredktrd ta tinat infurl JiEF in the maid mum. * 
ibreshald dwresso ZtllI is r&red for ldatltW& of 
splvane. Appliratiin of this tkrrsbdd id&i&d 10 (25%) d 
40 c&oi~patiants and 20 (61%) of 33 patk& ln the 
streptokiniw @‘@up (p < 0.005). 
Thus, intiawnws rtrept&lnase rtgnlLanUy rkangea 
the relation bzhwn predicted and l&ml mate mycurdW 
infarction sire, demo&ting the pntentlal al the @&rd 
ECG for noninvasive cvalwdtioli of myaeprdipl dvsgeafter 
thmmbotyiic therapy. 
In the 40 wntrol patients there WBF no change from 
ST-predicted to final QRS.estimrded infarct size (median 
17.7% verw 18.5%; p = NS,. In tke 33 patteotr in the 
streptokinase group, there w&s P highly significant decrease 
Thrombolytic therapy has been shown to reduce final infarct 
size U-3) in patients with acute myocardial infarction. In 
turn, reduction in infarct size has resulted in improvement of 
both left ventricular function and prognosis (4-7). Because 
thrombolytic therapy is therefore now routinely adminis- 
tered to patients with acute infarction. there is a need for 
noninvasive methods to evaluate its e&ctiveness. 
Treviour studies (B-10) have established the relation be- 
tween the acute myocardial infarct sire predicted by initial ST 
segment changes and that estimated by final QRS score in the 
absence ofrepafusion therapy. The most quantitative of these 
studies (IO) presented fomndas describing this relation for both 
anterior and inferior acute infarct locations. In an independent 
study (ll,lZL the formula for anterior location was validated 
and that for inferior location modified to include consideration 
of the full spectrum of electrocardiographic (ECG) leads. 
If the size of an acui~ myocardial infarction were limited 
by either spontaneous or therapeutic reperfusion. these 
Methods mmed from the initial ECG (Fig. I and 21. The following 
Study patienti. A detailed descriptton of pawat mroll- 
formulas baled on the numberofleads with STelevarion 1 t I 
ment in the Second Jnternational Study of Infarct Survival and the wn 141 of ST elevation were used for this prediction 
WS-2) was recently published IS). The effect on mortality 
IIO-12): 
of intravenous strcptokinase and oral aspirin treatment uw 
studied in patients with suspected myocardial infarction who 
were admitted within 24 h of symptom onset (I? h m the 
Danish rubpopulation). Patients were subsequently random- 
ized to four treatment groups: I) streptokinase alone. ?I 
aspirin alone, 3) both drugs. and 4) neither drug. The 
regimen for rtreptokinane (Sseptase) was I.5 x 10L U 
administered intravenously over I h and for aspirin 160 
mglday for 30 days. All patients admitted to Centofte Hos- 
pital and Rigshospitalet with suspected myocardial infarc- 
tion during 1986 and 1967 were considered for entry in the 
ISIM trial in the absence of the following non-ECG exclu- 
sion criteria: contraindication to streptokinase or aspirin 
(history of stroke, gastrointestinal bleeding or ulcer, hyper- 
tension >200/1GQ mm Hg or recent severe trauna or opera- 
tion) or the wesence of other life-limiting disease. 
Patients i‘n the ISIS-2 trial were included in the present 
studv if therr was no ECG evidence of earlier mvocwiial 
infarction. bundle branch or fascicular block. ventricular hy- 
pettrophy of ventricular paced rhylhm. Furthermore. ECG 
evidence of epicardial injury. es defined in Table 1. was 
required. Patients who received stmptokinax alone or strep 
tokinase and aspirin were considered as the streptokmase 
group; the patients who received aspirin or neither drug were 
considered as the control group based on the fact tha the 
aspirin alone has not been considered capable of limiting 
mywrdial infarct size. 
~Eleelroeardiographic consldetattmns. The ECG showmg 
the maximal ST ~eement deviation before treatment elloca- 
don was considered the initial recordmg and the final avail- 
M&r % Ml s,ze = 310.6 IP ST T m leads II, 111. aYFl+ 2.01 
ST elevlihon was measured lo the nearest 0.5 mm at the J 
point II01 in each lead except aVR. The formula for anterior 
myocardrd tnfarction is used wnh confidence because it has 
been vahdated (11.12). This particular formula was selected 
for infertor myocardial infarclion because it attained the 
highest correlation in both of the Danish populations in the 
Study by Clemmensen et al. (12) However, it is used with 
caution because it was modified empirically and has not yet 
been v&dated in an extenwe independent population. 
The QRS-estimated myocardial infarct size was deter. 
mined from the discharge ECG by using the Selvester QRS 
score Wg. I and 2); this scoring system and its application 
mode have previously been described in detail (12.13). The 
cystem contains 54 criteria awarding a maximum of 32 
points. each reoresentinr! approximately 3% infarction of the 
ieft ventr,cle. 
Data analysis. The initial ST segment-predicted infarct 
size and the final QRS-esttmated size were detemdned for all 
patxnts with use of the methods previously described. 
These two expression, were compared for all patients and 
Tar ~hc two mfaret locations within each croon. To orovide a _ 
qmntitawe expression of the results of thromb&tic ther- 
apy. the d&rcnce between the intt$l ST segment-predicted 
myocardtal infarct IMII swe and the final QRS-estimated stze 
was determined for each patlent as follows: 
able in-hospital ECG wa considered the Jircharge record- 
ing. The initial ECG was used to consider inclusion criteria 
Pcrccnt di%rcnce - 100 l&n31 QRS-ertrnalcd Ml size - lnhial 
(Table 1) and to classify the patients according to antermr or ST-predicted MI wet i tnmal ST-prediclcd MI size. 
Figare 1. Twelve lead ekcwxardmgrams from a padent with acute Use of this formula results in a negative percent difference in 
anterior myocardial infarction (MI). Calculalion of initial ST- 
predicted infarct size, final QRS-estimated infarct size and percent 
patients in wham the final QRS-estimated infarct size is 
difference isshown. 7 = elevation. 
smaller than the initial ST segment-predicted infarct size 
(Figs. I and 2) and a positive percent difference in patients 
whose final QRS-estimated infarct size is larger than the 
initial ST-predicted infarct size. 
When the final QRS-estimated mywardial infarct size is 
Figure 1. Twelve lead electrocardiograms from a patient with acute 
inferior myocardial infarction (M1). Calculation of initial ST- 
predicted infarct size, final QRS-estimated infarct size and percent 
difference isshown. S = sum; other abbreviations a in Figure 1. 
smaller than the initial ST-predicted myocardia infarct size, 
it becomes important to identify the threshold beyond which 
myocardial salvage can be considered to have occurred. The 
formula for determining the percent difference in infarct size 
was till1 applied in the mtrol goup, md IhS value tbal 
identified the lowest auari.le (below the ZSlb oercentde) was 
identified and design&d as this threshold. ?hhe proportions 
of patients in both control and strcptokinase groups falling 
below this :hreshold of ptrcen! difference in myocardiat 
infarct size were compared. 
Statistics. StatisIical analvsis was aerformed wine the 
Wilcoxon one-sample rank sint test a& the Mann-Whitney 
tw~sample rank sum test. Fisher’s exact test examined 
di&rences in proportions. Multiple regression analysis that 
adjusted for differences in initial ST-predicted infarct size 
was used to assess the e5ect of infarct location and strcp- 
tokinase treatment on the ditTerence between initial ST- 
predicted size and final QRS estimated infarct size. Two- 
sided p values 40.05 were considered significant. 
ReSUltS 
The study group. Of the 120 patients randomized to the 
ISIS-2 trial at Riishospitalet and Gentofte Hospital, 39 were 
excluded by ECG criteria and 8 were excluded by non-ECG 
criteria. The study final group consisted of 73 consecutive 
patients: 40 in the control group including 7 women (median 
age 5X years; range 36 to 71) and 33 in the streptokinase group 
including 5 women (median age 59 years; range 36 to 69). The 
median time to randomization was not significantly different 
between the control and streptokinase groups (2.8 h. range I to 
12 versus 3.6 h, range I to 12). In the slreptokinase group there 
was a trend toward earlier randomization in the inferior rather 
than in the anterior infarction group 0.3 h. range t to 7 versus 
4.0 h, raogc I to 12; p = 0.69). 
Initiat prediied versus final estimated infarct size (Table 
3). In the control group there was a nonsignificant (3%) 
increase from initial ST-predicted infarct size to final QRS- 
estimated infarct size. In the streptokinase group there wra 
a highly significant (26%) decrease from the predicted to the 
final infarct size (p < O.wO2). The median final myocardial 
infarct size was slightly, but not significantly, smaller in the 
streptokinase group than in the control group (16.2% versus 
l&3%, p = 0.22). 
Anterior wrsus iofcrtor infarction (Table 3:. The patients 
recetving slreptokittase to both mfarct location groups bad B 
significant decrease in final infarct size: infenor 45% (p = 
II.301  and anterior 18% (p < 0.03). There were more patients 
wtth a larger initial ST-predicted infarct size in the streptoki- 
nase group. However. a multiple regression analysis that 
corrected for these diffcrcnces confirmed the treatment 
effect of streptokinase (p = 0X06). This analysis also indi- 
cated that the infarct lo&ion had no significant effect on the 
difference between initial ST predicted and final QRS- 
estimated infarct size. 
In the control group, patients in the lowest quanile had a 
z?Q?Z decrease from initial ST-predicted to final QRS- 
estimated infarct size (Fig. 3). Using this as the minimal 
threshold for detection, 20 (61%) of 33 patients in the 
streptokinase group ver~os IO (25%) of 40 patients in !he 
control group were considered to have had myocardiat 
salvage lp < 0.005). 
Discussion 
Predicted and estimated infarct size. This study validates 
the previously established relation between initial ST- 
predicted myocardial infarct size and final QRS-estimated 
infarct size in control patients and demonstrates the beneti- 
cial effect in patients receiving thrombolytic therapy. The 
standard ECG used in this way may provide a new non- 
invasive approach for identifying patients who achieve 
myocardml salvage after thrambolytic therapy. One lim- 
itation is the necessity to exclude patients with factors 
such as bundle branch block and ventricular hypertrophy 
because the ECG indexes of ST-predicted and QRS- 
estimated myocardial infarct size have not been validated in 
their presence. 
Comparison with previous studies on evaluatittg re~ttlt~ of
rep&u&m therapy. The improved survival after thrombol- 
ysis for acute myocardial infarction is primarily attributed to 
reperfusion by way of a previously occluded coronary artery 
resulting in salvage of isohemic myocardium. The clinical 
Fiirc 3. Each patient’s (open rircW percent change fmm initial 
ST-predicted mycardial infarct (Mt) she to final QRS-estimated 
infare, S~EC in the control group Cn = 40) and the rtreptol;inare group 
(n = 33) is depicted. Wed drcks represent the median and bars the 
25th and7Sth percentilzlevelsfureachgrou~. Thebmkmlbxatthe 
25th percentile level fur the control group is the proposed threshold 
for detection ofmywardial salvage. Salvage is attributed to patients 
with a difference from predicted to final infarct size on orb&w this 
line. 
method for evaluation of the efiicacy of therapy has been 
primarily cardiac catheterization, which is an invasive and 
costly technique. To overcome these limitations, several 
clinical studies have focused on the ability to noninvasive- 
ly detect either myocardial rcperfusion using various 
methods (14-19) or myocardial salvage using the standard 
ECG (g-1 I). The studies by Askenazi et al. (8) and Yusuf et 
al. (9) first demonstrated that the final myocardial infarct size 
could be predicted using the initial acute ECG in pafients 
who did not receive size limiting therapy. They hypothesized 
that applying these methods in patients given such therapy 
could potentially assess the therapeutic effects. A more 
quanlitative ST predictive method was recently developed 
by Aldrich et al. (IO). This study, confirmed in an indepen- 
dent population (II), showed that the final QRS-estimated 
size of an initial myocardial infarction could be predicted 
from the ST segments on the admission ECG. 
Use of the ECG ro evaluate repetfusion rheropy has also 
been proposed by Blanke et al. (20) using the somewhat 
different perspective of following the evolution of Q and R 
waves after reperfusion. Their study showed trends toward 
early (48 h posladmission) disappearance of Q waves and 
increase in R uwe height in IS patients with reperfusion by 
way of the left anterior descending artery. Their restr!:fi 
cotafi~ the observation of Albert et al. (21) comparing 
resolution of QRS changes after inrraoperative myocardial 
ittfarciion during coronary artery bypass grafting and after 
nonoperative myocardial infarction. In the operative group 
with the infarcted region rep&used by way of the graft, a 
significantly greaterresolutionofQRS changes, asquantified 
by the Selvester QRS scoring system. occurred from day 5 to 
60 than in the nonoperative group. This difference persisted 
at I8 months‘ follow-up. 
Myocardiol salvage has o/so been suggested by invmi- 
garors comparing QRS changes befween ~ro~~ps of parients 
with or without infarct ormy potency. Hackworthy et al. 
(22) found a signiiiczmtly lower sum of Q waves in patients 
with reperfusion than in patients without roperfusion 24 h 
after treatment. Timmis et al. 03) found simtilicardlv more 
instances of non-Q wave myocardial infarction among pa- 
tients with either spontaneous or phamtacologically induced 
repetfttsion. In both of these studies (22,23) trends toward a 
smaller Selvester QRS score (24) were found in favor of 
patients with successful reprfusion. This is in accordance 
with the results of the present study of a lrettd toward a 
larger final QRS estimated myocardial infarct size ia eon- 
ventionally than in streptokinase-treated patients. Since 
myoardial salvage has bat shown (2) to he enhanced only 
by early lreatmem with thrombolytic therapy, the re!atively 
small difference in final QRS score in the two groups of this 
study could be due to inclusion of patients up to I2 h after 
symptom onset. 
Anterior venus inferior infawtion. The 26% overall re- 
duction in infarct size in the streptokinase group agrees with 
a previous controlled study by Simwns et al. (2) that used 
the enzyme whydroxy-butyrate dehydrogenase (HBDH) 
for estimation of infarct size. A median 30% reduction in 
infarct size was observed in padents receiving intracor- 
onaty streptokinase compared with lhose w&d conven- 
tionally. Bar et al. (25). also using HBDH. found approxi- 
mately equal reduction of anterior and inferior myocardial 
infarct size (37% and 33%) in Datierds receiwinp: either 
intracoronary or intravenous sireptokinase wh& com- 
pared with control paricnts. In the present study there was 
an apparent dilTerenLe in myocardial salvage in &vor of 
infe&r infarct location. That might result from earlier 
randomization in the inferior myocardial infarct group or 
from some inadequacy of the fortnula for estimating in- 
ferior infarct size. As stated in the Methods section, the 
formula fw inferior myocardial infarct size used in the 
wesent study was empirically selected and has been 
validated only in a small test population: thus, it should be 
used whh caution, It is reassuring that myoardial infarct 
location did not significantly affect the difference between 
predicted and final myocardial infarct size in the regression 
model. 
Cnnrl!!sinns. ?!!is s!$ :~ggrslr that myocardial sai- 
“age after tb,ombo,y,ic lherapy can he tdenufied and 
possibly quantified noninvasivcly from rhe ECG m pa- 
tients with an initial acute myoca,d~A mfarction. thuc p,o- 
viding a simple technique to cvaluatc the therapewc SW 
cess of such !herapy. This new diagnostic lool may be 
helpful in identifying patients with a large predicted myocar- 
dial infarct size who might benefit most from lhrombolytic 
therapy and also in evaluating the clinical outcome of aii 
patients who ,rc&e thenpy aimed ai myocardial reperfu- 
sion. 
